136 related articles for article (PubMed ID: 32108621)
1. Diagnostic utility of immunohistochemical marker prostein for evaluation of primary and metastatic prostatic carcinomas.
Garudadri G; Rao BV; Sundaram C; Fonseca D; Murthy SS; Sharma R; Rao TS
Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S18-S24. PubMed ID: 32108621
[TBL] [Abstract][Full Text] [Related]
2. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
3. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry in diagnostic surgical pathology of the prostate.
Hameed O; Humphrey PA
Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601
[TBL] [Abstract][Full Text] [Related]
5. Prostein expression in human tumors: a tissue microarray study on 19,202 tumors from 152 different Tumor entities.
Viehweger F; Böcker C; Weidemann S; Freytag M; Menz A; Büscheck F; Luebke AM; Putri D; Kluth M; Hube-Magg C; Hinsch A; Lennartz M; Lutz F; Reiswich V; Höflmayer D; Fraune C; Möller K; Bernreuther C; Lebok P; Sauter G; Steurer S; Dum D; Marx AH; Simon R; Krech T; Clauditz TS; Jacobsen F; Gorbokon N; Burandt E; Minner S; Kind S
Diagn Pathol; 2024 Jan; 19(1):12. PubMed ID: 38218896
[TBL] [Abstract][Full Text] [Related]
6. Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
Naik M; Rao BV; Challa S; Fonseca D; Sudha SM; Giridhar A; Sharma R; Raju KVVN; Rao TS
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147963
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.
Yin M; Dhir R; Parwani AV
Diagn Pathol; 2007 Oct; 2():41. PubMed ID: 17963516
[TBL] [Abstract][Full Text] [Related]
8. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Utility of Prostein, Uroplakin II and SATB2 for Diagnosing Carcinoma of Unknown Primary Origin: A Systematic Immunohistochemical Profiling.
Mochizuki K; Kawai M; Odate T; Tahara I; Inoue T; Kasai K; Nakazawa T; Katoh R; Kondo T
Anticancer Res; 2018 Aug; 38(8):4759-4766. PubMed ID: 30061246
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
11. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma.
Srinivasan M; Parwani AV
Diagn Pathol; 2011 Jul; 6():67. PubMed ID: 21777423
[TBL] [Abstract][Full Text] [Related]
13. HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin.
Varinot J; Cussenot O; Roupret M; Conort P; Bitker MO; Chartier-Kastler E; Cheng L; Compérat E
Virchows Arch; 2013 Dec; 463(6):803-9. PubMed ID: 24146108
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
[TBL] [Abstract][Full Text] [Related]
16. GATA3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall.
Tian W; Dorn D; Wei S; Sanders RD; Matoso A; Shah RB; Gordetsky J
Histopathology; 2017 Jul; 71(1):150-155. PubMed ID: 28316088
[TBL] [Abstract][Full Text] [Related]
17. Prostein expression is highly restricted to normal and malignant prostate tissues.
Kalos M; Askaa J; Hylander BL; Repasky EA; Cai F; Vedvick T; Reed SG; Wright GL; Fanger GR
Prostate; 2004 Aug; 60(3):246-56. PubMed ID: 15176054
[TBL] [Abstract][Full Text] [Related]
18. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma.
Bernacki KD; Fields KL; Roh MH
Diagn Cytopathol; 2014 Jul; 42(7):570-5. PubMed ID: 24273068
[TBL] [Abstract][Full Text] [Related]
19. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
20. Histomorphological study of prostatic adenocarcinoma and its mimics.
Mahapatra QS; Mohanty P; Nanda A; Mohanty L
Indian J Pathol Microbiol; 2019; 62(2):251-260. PubMed ID: 30971549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
